Unicycive Therapeutics, Inc.

Contributing Author

Recent Articles by Unicycive Therapeutics, Inc.

Nov-12	Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update UNCY GlobeNewswire
Nov-03	Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference UNCY GlobeNewswire
Oct-30	Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference UNCY GlobeNewswire
Oct-28	Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End UNCY GlobeNewswire
Aug-26	Unicycive Therapeutics to Participate in Upcoming Investor Events in September UNCY GlobeNewswire
Aug-18	Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease UNCY GlobeNewswire
Aug-14	Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update UNCY GlobeNewswire
Jul-24	Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology UNCY GlobeNewswire
Jul-08	Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement UNCY GlobeNewswire
Jul-07	Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference UNCY GlobeNewswire
Jun-30	Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis UNCY GlobeNewswire
Jun-17	Unicycive Therapeutics, Inc. Announces Reverse Stock Split UNCY GlobeNewswire
Jun-10	Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis UNCY GlobeNewswire
May-22	Unicycive Therapeutics to Present at Upcoming Investor Conferences UNCY GlobeNewswire
May-21	Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders UNCY GlobeNewswire
May-14	Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update UNCY GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.